Gold(III) Complexes for Antitumor Applications: An Overview.

Clicks: 350
ID: 95439
2018
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #17 of 117 articles by views in Chemistry (Weinheim an der Bergstrasse, Germany)

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Abstract
Gold(III) complexes have emerged as a versatile and effective class of metal-based anticancer agents. The development of various types of ligands capable of stabilizing the Au cation and preventing its reduction under physiological conditions, such as chelating nitrogen-donors, dithiocarbamates and C^N cyclometalled ligands, has opened the way for the exploration of their potential intracellular targets and action mechanisms. At the same time, the bioconjugation of Au complexes has emerged as a promising strategy for improving the selectivity of this class of compounds for cancer cells over healthy tissues, and recent developments have shown that combining gold complexes with molecular structures that are specifically recognized by the cell can exploit the cell's own transport mechanisms to improve selective metal uptake.
Reference Key
bertrand2018goldiiichemistry Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Bertrand, Benoît;Williams, Morwen R M;Bochmann, Manfred;
Journal Chemistry (Weinheim an der Bergstrasse, Germany)
Year 2018
DOI
10.1002/chem.201800981
URL
Keywords

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

No comments yet. Be the first to comment on this article.